Observational Study to Observe the Efficacy of Levemir® (Insulin Detemir) in Patients With Type 2 Diabetes.

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT00793273

NN304-3694

Details and patient eligibility

About

This study is conducted in Europe. The aim of this observational study is to observe the efficacy of Levemir® treatment in patients with type 2 diabetes in everyday clinical practice in Switzerland. Furthermore the time period between diagnosis of type 2 diabetes and insulin initiation is evaluated.

Enrollment: 1,074 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes mellitus
• Insulin-naive or currently treated with another basal insulin
• Inclusion of patients at the discretion of the treating physician after the decision to prescribe Levemir®

Exclusion criteria

• Type 1 diabetes mellitus
• Patients treated with short acting or with premix insulin
• Women who are pregnant, breast feeding or have the intention to become pregnant
• Known or suspected allergy to the study product or related product
• Any exclusion criteria according to the Swiss Levemir® SPC (Summary of Product Characteristics)

Trial design

1,074 participants in 1 patient group

A

Treatment:

Drug: insulin detemir